Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Jun 13, 2023
Finance
Turnstone to test public markets’ appetite for a biotech still waiting for clinical data
Now focused on TILs with data due in mid-2024, the company would be the fourth biotech to raise at least $20M in a NASDAQ listing this year
BioCentury | Oct 7, 2022
Discovery & Translation
Galixir’s rapid PROTAC design; plus Engimmune’s TCR platform and more
BioCentury’s roundup of translational news
BioCentury | Sep 13, 2019
Emerging Company Profile
Valo: adding tumor antigens to oncolytic viruses
Valo’s platforms use physical interactions for viral display of tumor antigens without genetic engineering
BioCentury | Aug 22, 2019
Emerging Company Profile
Tscan: Tracking down novel T cell targets
Tscan is finding novel TCR-antigen pairs with its peptidome screening platform
BioCentury | Dec 21, 2018
Product R&D
Cell therapies seek solid ground
How mosaic antigen expression makes solid tumors hard nuts to crack
BioCentury | Sep 9, 2017
Strategy
Some of the parts
Can Gilead apply its combination chops to make Kite CAR Ts work in solid tumors?
Items per page:
1 - 10 of 45